RO7446603
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for RO7446603, covering 2026-03-30 to 2026-04-27. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema [Phase 1, Phase 2]